Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $13.5200 (-0.52%) ($13.1500 - $13.8000) on Thu. Feb. 11, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 11.32% (three month average) | RSI | 3 | Latest Price | $13.5200(-0.52%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -3.9% a day on average for past five trading days. | Weekly Trend | ADMS declines -16.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(35%) IBB(32%) ARKG(24%) IWO(23%) IWM(22%) | Factors Impacting ADMS price | ADMS will decline at least -5.66% in a week (0% probabilities). VIXM(-15%) UUP(-9%) BNDX(-8%) TLT(-7%) SHY(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -5.66% (StdDev 11.32%) | Hourly BBV | 0 () | Intraday Trend | 2.3% | | | |
|
1 - 5 Day Possible Target | $-18.32(-235.5%) | Resistance Level | $18.23 | 5 Day Moving Average | $14.03(-3.64%) | 10 Day Moving Average | $15.33(-11.81%) | 20 Day Moving Average | $18.23(-25.84%) | To recent high | -56.2% | To recent low | 0.1% | Market Cap | $382m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |